Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains over 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
BofA Securities Reiterates Underperform Rating on Fulcrum Therapeutics (FULC)
May 14, 2024 8:47 AM EDTBofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $5.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).
The analyst comments "FULC announced the company has entered an exclusive license agreement with Sanofi (ticker: SNY; covered by Graham Perry) for the ex-US development of losmapimod in... More
Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel
May 13, 2024 12:31 PM EDTStifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $22.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "Ph.3 REACH (facioscapulohumeral muscular dystrophy [FSHD]) data in 4Q24 are the main focus for FY2024, and we're... More
